Sermorelin (10mg)
Sermorelin is a synthetic 29-amino-acid analog comprising the first 29 residues of growth hormone-releasing hormone (GHRH), investigated extensively in research as the prototype GHRH analog.
About Sermorelin
Sermorelin (GRF 1-29) is a synthetic peptide consisting of the first 29 amino acids of human growth hormone-releasing hormone (GHRH) — the portion that retains full biological activity at the GHRH receptor. It is the longest-studied GHRH analog and served historically as a diagnostic tool in growth hormone deficiency research before becoming a research compound in adult GH-axis literature.
Mechanism in Research Literature
Research on Sermorelin has documented:
- Binding to GHRH receptors in the anterior pituitary
- Stimulation of endogenous growth hormone release
- Short half-life (~10 minutes) preserving pulsatile GH release pattern
- Downstream IGF-1 elevation with sustained use
- Modulation of sleep-associated GH release in research models
Research Context
Sermorelin has been investigated in studies exploring:
- GHRH receptor pharmacology
- Diagnostic evaluation of pituitary GH reserve
- Adult GH-axis research
- Comparative pharmacology vs. other GHRH analogs (CJC No DAC, Tesamorelin)
- Combination research with ghrelin receptor agonists
Related Research Peptides
Sermorelin appears in literature alongside other GHRH analogs (CJC No DAC, Tesamorelin), ghrelin agonists (Ipamorelin), and downstream IGF-1 research compounds (IGF-1 LR3).
For research use only. Not for human consumption. Not intended to diagnose, treat, cure, or prevent any disease.
